Author Archive: Tracy Cooley

Tracy Cooley

Tracy serves as the Director of Events Communications and handles all communications for BIO’s events and emerging company policy issues. She loves blogging and podcasting on all things biotech and believes in the great potential of the industry, looking for every opportunity to spread the message far and wide. Nearly everyone in her family is a golfer, and as such, she has what many people have called a “natural” swing. Sometimes she even hits the ball. Tracy just finished her ninth marathon, and has nearly mastered the skill of one-foot-in-front-of-the-other (usually, sometimes the laces get in the way). The joy of her life is her five-year-old daughter Josephine.

Latest Posts

Gates Foundation and Grand Challenge Partners Announce New Investments in Breakthrough Science

Vaccination

At an event in Seattle today, the Bill & Melinda Gates Foundation and a group of international partners announced three new initiatives aimed at encouraging breakthroughs in science. The event celebrates a decade of progress since the Gates Foundation’s launch of the initial Grand Challenges in Global Health initiative, which was created to catalyze scientific and technological innovation to achieve major breakthroughs in global health. The three new initiatives include: • All Children Thriving – Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , ,

New PhRMA report: Nearly 800 Cancer Medicines in Development

vaccines

A new report from the Pharmaceutical Research and Manufacturers of America (PhRMA) shows that biopharma companies are currently developing nearly 800 new medicines and vaccines for cancer. “In recent decades, we have seen great progress in developing effective cancer treatments that help extend lives, improve quality of life and increase productivity,” said PhRMA President and CEO John J. Castellani. “Continued research has expanded our knowledge of how cancer develops and how to target medicines for Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

Washington Post: Why Extremely Expensive Drugs Are Often Worth the Cost

Breast Cancer

Jason Millman highlights a new study published in Health Affairs showing specialty drugs often provide ‘substantially much higher health benefits than the traditional drugs.’ “Our study suggests that although specialty drugs often have higher costs than traditional drugs, they also tend to confer greater benefits and hence may still offer reasonable value for money,” wrote the researchers at the Boston-based Center for Value and Risk in Health. The study authors judged the drugs’ performance by Read More >

Health  |  1 Comment  |  Email This Post
Tags: , , , ,

Health Affairs: 5 Myths about Cancer Care in America

lab_tech

In the latest issue of Health Affairs, Dana Goldman of the University of Southern California in Los Angeles and Tomas Philipson at the University of Chicago – two of the nation’s leading economists – debunk the most common misconceptions about cancer treatment. They argue that evidence shows that patients value these treatments more highly than what is illustrated through traditional cost-effectiveness analysis. Furthermore, they assert coverage policies that place an undue burden on patients are Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , ,

Cancer drugs save and extend lives

medical_research

This week, CBS aired a misleading segment on the cost of innovative cancer therapies. BIO immediately responded by pointing out that the segment completely ignored the value created by these drugs for patients and the healthcare system. “Cancer patients today are able to live longer and enjoy a higher quality of life than ever before thanks to medicines made by biopharmaceutical research companies,” said Jim Greenwood, BIO President and CEO. “Advances in cancer treatment are Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,